Critical limb ischemia (CLI) is a kind of peripheral arterial disease (PAD) in which chronic inflammation associated with atherosclerosis (progressive thickening of arteries lining) causes reduced blood flow to the extremities (legs, feet and hands), leading to severe pain and ulcers or sore. Some major risk factors for critical limb ischemia comprise aging (people aged 60 or over are at high risk of developing this diseased condition), diabetes, obesity, high cholesterol level, sedentary lifestyle, smoking and high blood pressure. Critical limb ischemia is associated with most common symptoms such as severe pain and numbness in the legs and feet when a person is in sedentary stage (rest pain), ulcers or skin sores and tissue necrosis (gangrene).
Worldwide increasing geriatric population, rising incidence of CLI and participation of a large number of companies to develop drugs supposed to treat CLI are among the major factors driving the market growth across the globe. Statistics released by the United Nations (UN) suggest that the global share of elderly population (aged 60 years and over) as a proportion of the global population has been increased from 9.2% in 1990 to 11.7% in 2013, and is expected to reach 21.1% by the end of 2050. In 2013, nearly 841 million people were aged 60 years and over which is likely to reach more than 2 billion by 2050.
As people age they are at high risk of developing CLI, therefore, increasing elderly population is expected to drive the market growth during the forecast period. According to Vascular Disease Management, the prevalence of CLI has been estimated to be 300 per million inhabitants. In the United States, approximately 1 million people are affected with CLI. However, an analysis suggested by the Sage Group indicates that nearly 2 million people in the U.S. are living with CLI and owing to continuous rise in geriatric population the prevalence is expected to reach 3.5 million by 2020. Such high prevalence of people with CLI represents a favorable market for critical limb ischemia treatment market. In terms of geography, North America, Europe, Asia-Pacific and Rest of the World (RoW) are the four major markets for critical limb ischemia. Of these North America represents the largest market, followed by Europe, Asia-Pacific and Rest of the World (RoW).
Some of the major companies and research institution that are actively participating to develop medicines for treating critical limb ischemia include Aastrom Biosciences, Mahidol University, University Hospital Ostrava, MultiGene Vascular Systems Ltd. University of Southern California, Harvest Technologies, Seoul Veterans Hospital, GWT-TUD GmbH, Biotronik AG, United Therapeutics, Sanofi, Asklepios Kliniken Hamburg GmbH, Anesiva, Inc. and medac GmbH.